The startup QuantHealth raised $45 million for AI technology for clinical trial planning
QuantHealth, a company developing AI-based simulations for clinical trials, has raised $45 million in a Series B funding round. The total amount raised by the company has now reached $75 million.
QuantHealth, a company developing AI-based simulations for clinical trials, has raised $45 million in a Series B round led by the growth fund Qumra Capital, with the participation of other investors. Among them: Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures, Esplanade Ventures, and others. To date, the company has raised $75 million, including the current round. Past investors in the company included the pharmaceutical company Sanofi, the investment fund of the consulting giant Accenture Ventures, and others.
The company was founded in 2020 by Or Inbar, from the company Concert AI, and Arnon Horev, who previously led the business operations of the life sciences company Nucleai and managed the marketing and sales department of EarlySense. Today, the company has about 85 employees in offices in New York and Tel Aviv.
Clinical trials continue to be one of the most expensive stages with the highest levels of uncertainty in drug development. More than 90% of drugs that enter clinical development do not ultimately reach the market, and about 75% of them fail due to efficacy and safety issues. Given the increasing pressure to accelerate the arrival of drugs to the market due to growing competition from the East and rising operating costs, pharmaceutical and biotechnology companies are increasingly adopting predictive technologies for decision-making.
QuantHealth's technology allows companies and organizations to move from planning clinical trials based on past data and subjective assumptions to significant efficiency, executing trials where risks and weaknesses have been substantially reduced through AI-based simulations, even before recruiting the first patient for the trial or allocating the required capital.
"Today, decisions in clinical development are mostly made through a process of trial and error in the real world: conducting trials, waiting for results, and making adjustments, at high costs and with a significant level of risk. We are changing this model from the ground up," says Or Inbar, CEO and co-founder of QuantHealth. "Through our predictive simulations, teams can evaluate clinical and commercial decisions even before recruiting a single patient or committing to capital investment."
To date, QuantHealth has performed simulations in more than 600 clinical trials across 30 different medical indications, achieving a predictive accuracy level of up to 90%. The company plans to expand its operations to more than 40 medical indications in its core focus areas, including oncology, cardio-metabolic diseases, and inflammatory diseases.
